Perbedaan Organon Pharma Indonesia Tbk. dan Trimegah Karya Pratama Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Trimegah Karya Pratama Tbk. diperdagangkan di Rp155 (kapitalisasi pasar 314,02 M, volume 24 jam 49,33 jt). Perbedaan utamanya: Trimegah Karya Pratama Tbk. jauh lebih besar — sekitar 3× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | UVCR | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 314,02 M |
Volume | — | 49,33 jt |
Lot | — | 493,25 rb |
Perputaran | — | 7,55 M |
Harga Rata-rata | — | 153,12 |
Nilai Transaksi | — | 7,55 M |
Harga Ekuilibrium Indikatif | — | 155 |
Volume Ekuilibrium Indikatif | — | 3,77 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Selengkapnya di halaman UVCR →